Avalyn Pharma (AVLN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $23.66, -3.98% vs the prior close of $24.64.
- Volume 291.43K shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AVLN slides 4.0% to $23.66, a 6-month low. Closed at $23.66, -3.98% vs the prior close of $24.64. Day range $23.53–$24.72, opened at $24.72.
AVLN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AVLN slides 4.0% to $23.66, a 6-month low
- Closed at $23.66, -3.98% vs the prior close of $24.64. Day range $23.53–$24.72, opened at $24.72.
- Volume was 291.43K shares, 1.1x its 50-day average of 256.77K.
- Price is -27.1% vs its 50-day average ($32.44).
- 52-week range $22.68–$40.17; today's close sits at 6% of that range, 41.1% below the 52-week high.
Oct 15, 2026 — AVLN jumps 4.0% to $24.64
- Closed at $24.64, +4.01% vs the prior close of $23.69. Day range $23.59–$25.14, opened at $23.88.
- Volume was 199.40K shares, 0.8x its 50-day average of 256.56K.
- Price is -24.5% vs its 50-day average ($32.62).
- 52-week range $22.68–$40.17; today's close sits at 11% of that range, 38.7% below the 52-week high.
Oct 14, 2026 — AVLN ends flat (-0.2%) to $23.69, a 6-month low, 3 down days in a row
- Closed at $23.69, -0.21% vs the prior close of $23.74. Day range $22.68–$24.15, opened at $23.69.
- Volume was 267.80K shares, 1.1x its 50-day average of 254.73K.
- Price is -27.7% vs its 50-day average ($32.76).
- 52-week range $22.68–$40.17; today's close sits at 6% of that range, 41.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — AVLN slides 4.3% to $23.74, a 6-month low
- Closed at $23.74, -4.27% vs the prior close of $24.80. Day range $23.08–$25.27, opened at $24.66.
- Volume was 403.90K shares, 1.6x its 50-day average of 248.87K.
- Price is -27.9% vs its 50-day average ($32.90).
- 52-week range $23.08–$40.17; today's close sits at 4% of that range, 40.9% below the 52-week high.
Oct 12, 2026 — AVLN slides 3.7% to $24.80, a 3-month low
- Closed at $24.80, -3.73% vs the prior close of $25.76. Day range $24.70–$25.93, opened at $25.64.
- Volume was 133.30K shares, 0.5x its 50-day average of 248.74K — lighter than usual.
- Price is -24.8% vs its 50-day average ($33.00).
- 52-week range $24.14–$40.17; today's close sits at 4% of that range, 38.3% below the 52-week high.
Oct 9, 2026 — AVLN ends flat (+0.2%) to $25.76, 3 up days in a row
- Closed at $25.76, +0.16% vs the prior close of $25.72. Day range $25.22–$26.33, opened at $25.70.
- Volume was 241.80K shares, 1.0x its 50-day average of 246.28K.
- Price is -22.1% vs its 50-day average ($33.08).
- 52-week range $24.14–$40.17; today's close sits at 10% of that range, 35.9% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — AVLN rises 0.7% to $25.72 on 3.8x normal volume
- Closed at $25.72, +0.74% vs the prior close of $25.53. Day range $24.14–$25.82, opened at $25.32.
- Volume was 883.80K shares, 3.8x its 50-day average of 230.85K — unusually heavy trading.
- Price is -22.4% vs its 50-day average ($33.15).
- 52-week range $24.14–$40.17; today's close sits at 10% of that range, 36.0% below the 52-week high.
Oct 7, 2026 — AVLN rises 0.4% to $25.53
- Closed at $25.53, +0.39% vs the prior close of $25.43. Day range $25.26–$26.31, opened at $25.30.
- Volume was 202.90K shares, 0.9x its 50-day average of 230.49K.
- Price is -23.1% vs its 50-day average ($33.20).
- 52-week range $24.15–$40.17; today's close sits at 9% of that range, 36.4% below the 52-week high.
Oct 6, 2026 — AVLN slides 5.9% to $25.43, a 3-month low
- Closed at $25.43, -5.92% vs the prior close of $27.03. Day range $25.06–$27.22, opened at $27.22.
- Volume was 260.60K shares, 1.1x its 50-day average of 229.15K.
- Price is -23.5% vs its 50-day average ($33.24).
- 52-week range $24.15–$40.17; today's close sits at 8% of that range, 36.7% below the 52-week high.
Oct 5, 2026 — AVLN slides 3.9% to $27.03, a 1-month low on 1.9x normal volume
- Closed at $27.03, -3.91% vs the prior close of $28.13. Day range $26.26–$28.21, opened at $27.98.
- Volume was 427.30K shares, 1.9x its 50-day average of 223.40K — unusually heavy trading.
- Price is -18.8% vs its 50-day average ($33.29).
- 52-week range $24.15–$40.17; today's close sits at 18% of that range, 32.7% below the 52-week high.
Oct 2, 2026 — AVLN rises 2.6% to $28.13 on 2.4x normal volume
- Closed at $28.13, +2.59% vs the prior close of $27.42. Day range $27.72–$28.92, opened at $28.59.
- Volume was 526.20K shares, 2.4x its 50-day average of 218.51K — unusually heavy trading.
- Price is -15.5% vs its 50-day average ($33.31).
- 52-week range $24.15–$40.17; today's close sits at 25% of that range, 30.0% below the 52-week high.
AVLN latest news & SEC filings
Every SEC filing by or about AVLN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 17, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$28.93M (prior year -$20.19M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.98 (prior year -$17.63) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 1, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Things to know before you trade AVLN
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: Jun 3, 2026. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.04% (largest 8.6%). That is a volatile stock.
- Liquidity: about 317.22K shares (≈$7.51M) trade per day on average.
- 52-week position: $23.66 vs a range of $22.68–$40.17 (6% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 24 open-market buys, 0 sales; latest: Holdings A/S Novo bought 555,555 shares on May 1, 2026.
- Latest filings: 8-K Sep 16, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
AVLN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 24.72 | 24.72 | 23.53 | 23.66 | 291.43K |
| Oct 15, 2026 | 23.88 | 25.14 | 23.59 | 24.64 | 199.40K |
| Oct 14, 2026 | 23.69 | 24.15 | 22.68 | 23.69 | 267.80K |
| Oct 13, 2026 | 24.66 | 25.27 | 23.08 | 23.74 | 403.90K |
| Oct 12, 2026 | 25.64 | 25.93 | 24.70 | 24.80 | 133.30K |
| Oct 9, 2026 | 25.70 | 26.33 | 25.22 | 25.76 | 241.80K |
| Oct 8, 2026 | 25.32 | 25.82 | 24.14 | 25.72 | 883.80K |
| Oct 7, 2026 | 25.30 | 26.31 | 25.26 | 25.53 | 202.90K |
| Oct 6, 2026 | 27.22 | 27.22 | 25.06 | 25.43 | 260.60K |
| Oct 5, 2026 | 27.98 | 28.21 | 26.26 | 27.03 | 427.30K |
| Oct 2, 2026 | 28.59 | 28.92 | 27.72 | 28.13 | 526.20K |
| Oct 1, 2026 | 28.48 | 28.69 | 26.86 | 27.42 | 423.60K |
| Sep 30, 2026 | 27.05 | 29.00 | 26.57 | 28.49 | 347.60K |
| Sep 29, 2026 | 27.67 | 28.67 | 27.01 | 27.10 | 422.00K |
| Sep 28, 2026 | 27.92 | 28.80 | 27.27 | 28.32 | 205.90K |
| Sep 25, 2026 | 28.52 | 28.53 | 27.00 | 28.08 | 223.10K |
| Sep 24, 2026 | 29.70 | 30.16 | 27.40 | 28.55 | 221.20K |
| Sep 23, 2026 | 32.19 | 32.54 | 29.14 | 29.67 | 252.00K |
| Sep 22, 2026 | 31.94 | 33.18 | 31.00 | 32.45 | 233.30K |
| Sep 21, 2026 | 31.34 | 33.00 | 30.97 | 31.62 | 177.30K |
About Avalyn Pharma
Avalyn Pharma (AVLN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1540171.
AVLN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lyn Baranowski | Chief Executive Officer | May 1, 2026 |
| Jill Carroll | Director | May 1, 2026 |
| Jon Congleton | Director | May 1, 2026 |
| David Matthew Friedman | Director | Apr 29, 2026 |
| Kate Haviland | Director | May 1, 2026 |
| Erin Lavelle | Director | May 1, 2026 |
| Robert J. Meyer | Director | Sep 17, 2026 |
| Heather D Turner | Director | May 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Lyn Baranowski | Chief Executive Officer | May 1, 2026 |
| Douglas R Carlson | Chief Financial Officer | May 1, 2026 |
| Adam H. Golden | General Counsel | May 4, 2026 |
| Howard Lazarus | Chief Medical Officer | May 1, 2026 |
| Melissa Rhodes | Chief Operating Officer | May 1, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 1, 2026 | Holdings A/S Novo | Buy | 555,555 | $18.00 |
| May 1, 2026 | Holdings A/S Novo | Buy | 555,555 | $18.00 |
| May 1, 2026 | Holdings A/S Novo | Buy | 555,555 | $18.00 |
| May 1, 2026 | Holdings A/S Novo | Buy | 555,555 | $18.00 |
| May 1, 2026 | Jill Carroll | Buy | 277,778 | $18.00 |
| May 1, 2026 | Jill Carroll | Buy | 277,778 | $18.00 |
| May 1, 2026 | Jill Carroll | Buy | 277,778 | $18.00 |
| May 1, 2026 | Jill Carroll | Buy | 277,778 | $18.00 |
| May 1, 2026 | Simeon George | Buy | 277,777 | $18.00 |
| May 1, 2026 | Simeon George | Buy | 277,778 | $18.00 |
| May 1, 2026 | Simeon George | Buy | 277,777 | $18.00 |
| May 1, 2026 | Simeon George | Buy | 277,778 | $18.00 |
| May 1, 2026 | One Capital Management, Llc Sr | Buy | 277,777 | $18.00 |
| May 1, 2026 | One Capital Management, Llc Sr | Buy | 277,778 | $18.00 |
| May 1, 2026 | One Capital Management, Llc Sr | Buy | 277,777 | $18.00 |
AVLN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $425.45M, total liabilities $27.10M, cash $264.20M (as of Jun 30, 2026).
AVLN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $37.38 |
| Jun 3, 2026 | 8-K Item 2.02 (results) | $26.40 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AVLN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.